Pneumococcal Disease News and Research

RSS
Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Antibiotic-resistant pneumococci increase rate of bacterial infections in children

Antibiotic-resistant pneumococci increase rate of bacterial infections in children

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

Glaxosmithkline, Pfizer will supply 60M doses of reduced-price pneumococcal vaccines to developing countries over 10 years, GAVI says

Pfizer to supply pneumococcal conjugate vaccines for infants and children

Pfizer to supply pneumococcal conjugate vaccines for infants and children

Pharmaceutical firms, GAVI Alliance agree to provide long-term supply of Pneumococcal vaccine

Pharmaceutical firms, GAVI Alliance agree to provide long-term supply of Pneumococcal vaccine

Vaccine deal signed - 47 developing countries to receive low priced vaccines by 2015

Vaccine deal signed - 47 developing countries to receive low priced vaccines by 2015

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

GAVI calls meeting with existing, potential donors

GAVI calls meeting with existing, potential donors

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

FDA and PATH collaborate to advance pneumococcal vaccine development for children

FDA and PATH collaborate to advance pneumococcal vaccine development for children

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert honored with PACE Global Leadership Award

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer's new pipeline shows growth and diversity in research and development

Sinovac prices public offering at $5.75 per common share

Sinovac prices public offering at $5.75 per common share

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech announces financial update, new joint ventures and developments